The Eureka Clinical AI platform now has advanced clinical AI and deep learning technology to support clinicians for fast and accurate prostate cancer detection and diagnosis using bpMRI and AI
TeraRecon, a ConcertAI company, has partnered with US-based Bot Image to add prostate cancer detection and diagnosis feature into the former’s Eureka Clinical AI platform.
The Eureka Clinical AI platform now has advanced clinical artificial intelligence (AI) and deep learning technology to support clinicians for fast and accurate prostate cancer detection and diagnosis using bpMRI and AI.
According to TeraRecon president Dan McSweeney, the Eureka Clinical AI platform powers first, second, and third-party algorithms on one consolidated platform.
It also easily integrates into the picture archiving and communication system (PACS) and provides a console to view all results and conversations across the healthcare teams of patients.
ConcertAI CEO Jeff Elton said: “We’re very excited to add Bot Image to our partner ecosystem and to provide ProstatID to the Eureka Clinical AI Platform.
“Prostate cancer is so devasting to men around the world, and bringing a solution that aims to provide AI-driven analysis that may improve the accuracy and speed of prostate cancer detection and diagnosis is critical. We look forward to making ProstatID available to all of our customers and their patients.”
In July 2022, the US Food and Drug Administration (FDA) granted approval to Bot Image’s AI software ProstatID for prostate cancer (PCa) screening, detection, and diagnosis.
Its ProstatID, a prostate AI software, is said to have improved PCa detection and diagnostic accuracy. It has also reduced false positives that could otherwise prompt unnecessary and costly biopsies.
Additionally, ProstatID can be utilised as a regularly scheduled screening mechanism due to its unique FDA clearance for screening utilising bi-parametric MRI.
According to ConcertAI, the software is suitable for active monitoring to track the development of the disease.
Bot Image CEO Randall Jones said: “With a global installed base of about 1,900 health sites, TeraRecon represents a significant and immediate distribution opportunity for the unique analysis capabilities of Bot Image, Inc.’s prostate solutions.
“We are thrilled to be a part of the TeraRecon AI partner ecosystem and to offer our solutions on the Eureka Clinical AI Platform and to all healthcare providers needing these services in a streamlined and best-in-breed ecosystem that TeraRecon offers.”